Xenon Pharmaceuticals Inc(NASDAQ:XENE) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 3, 2016. Company reported revenue of $413.00K. Analysts estimated a revenue of $2.25M. Earnings per share were $-0.42. Analysts had estimated an EPS of $-0.48.
Xenon Pharmaceuticals Inc (XENE) made into the market gainers list on Fridays trading session with the shares advancing 2.04% or 0.16 points. Due to strong positive momentum, the stock ended at $7.99, which is also near the day’s high of $7.99. The stock began the session at $7.64 and the volume stood at 4,228 shares. The 52-week high of the shares is $11 and the 52 week low is $5.6501. The company has a current market capitalization of $115 M and it has 1,44,26,370 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jun 28, 2016, Ian Mortimer (CFO) purchased 5,300 shares at $6.20 per share price.Also, On Sep 24, 2015, Y. Paul Goldberg (VP of Clinical Development) sold 22,149 shares at $8.98 per share price.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company has built a core platform Extreme Genetics enabling the discovery of validated drug targets by studying rare human diseases with extreme traits including diseases caused by mutations in ion channels known as channelopathies. Its product pipeline includes Glybera which is a gene therapy approved in the EU for the treatment of patients with the orphan lipid disorder LPLD; TV-45070 which is a small-molecule inhibitor of the sodium channel Nav1.7; GDC-0276 which is a selective oral Nav1.7 small-molecule inhibitor being developed for the treatment of pain and XEN801 which is a selective small molecule inhibitor of SCD1 being developed for the treatment of dermatological disorders. FDA has granted fast track designations to TV-45070 for EM and to Glybera for LPLD and received orphan drug designation.